Dupixent COPD denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for COPD Under Step Therapy

A step-therapy (also called "fail-first") denial means UnitedHealthcare requires that you try and document inadequate response to one or more specified lower-cost or formulary-preferred therapies before it will cover Dupixent (dupilumab) for COPD. This is among the most common denial types for biologics. The plan's position is that standard maintenance therapies — typically including combinations of long-acting bronchodilators and inhaled corticosteroids — must be tried first.

Step-therapy denials are frequently overturned when the patient has already tried the required therapies and documented the outcomes, or when the prescriber can demonstrate that the required step therapies are clinically inappropriate for this patient's specific disease endotype.

## Federal Appeal Rights

• ERISA §503 guarantees a full-and-fair internal review with written denial reasoning, including the specific step-therapy criteria applied.
• ACA §2719 provides independent external IRO review rights if the internal appeal fails — at no cost to you.
• Many states have enacted step-therapy exception laws that provide additional protections; check whether your state law applies to your plan type.
• Internal appeal: typically 180 days from denial notice.
• External review: typically 4 months from final internal denial.
• Expedited review: available when standard timelines would seriously jeopardize your health.

## The Central Question: Have the Required Steps Been Tried?

Obtain UHC's current step-therapy protocol for dupilumab in COPD. This will list the specific required prior therapies. Then determine:

1. Already completed the steps — if you have tried and documented inadequate response to all required therapies, the appeal is primarily a documentation exercise. 2. Steps clinically inappropriate — if a required therapy is contraindicated, has already failed, or is clinically inappropriate for your type-2 inflammatory COPD endotype, your prescriber must document that specific clinical reason.

## What to Gather

1. UHC's step-therapy protocol — request the exact document; you are entitled to the specific criteria used to deny coverage. 2. Prior therapy history — a dated list of every required step therapy tried, with start/stop dates, doses used (from your medical record), reasons for discontinuation, and documented outcomes (continued exacerbations, adverse effects, inadequate symptom control). 3. Prescriber medical-necessity and step-therapy exception letter — your physician should (a) confirm each step was tried with dates and outcomes, (b) explain why dupilumab is the appropriate next step for your eosinophilic/type-2 COPD endotype, and (c) cite the FDA-approved prescribing label and applicable guideline organization (e.g., GOLD, relevant pulmonology society). 4. Diagnosis and phenotype documentation — chart notes establishing COPD, type-2 inflammatory markers, and exacerbation burden. 5. Pharmacy records — dispense history showing actual fills of required prior therapies.

## Criteria-Mapping Structure

| Step Requirement | Evidence of Completion or Exception | |---|---| | Required Step 1 therapy trialed | Prescription fill dates, chart notes, outcome documented | | Required Step 2 therapy trialed | Same | | Exception: step clinically inappropriate | Prescriber note with specific clinical reason and chart basis | | Dupilumab appropriate next step | FDA label indication, guideline org reference, prescriber attestation |

IRO reviewers frequently overturn step-therapy denials when the patient's chart clearly documents trial and failure of required steps. Submit complete pharmacy records alongside the prescriber letter.